# Combined Treatment of Camrelizumab and Bevacizumab for Adult Patients with Recurrent Glioblastoma (GBM)

> **NCT04952571** · PHASE2 · TERMINATED · sponsor: **Beijing Sanbo Brain Hospital** · enrollment: 3 (actual)

## Conditions studied

- Recurrent Glioblastoma

## Interventions

- **DRUG:** Camrelizumab and Bevacizumab

## Key facts

- **NCT ID:** NCT04952571
- **Lead sponsor:** Beijing Sanbo Brain Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-06-27
- **Primary completion:** 2022-12-31
- **Final completion:** 2022-12-31
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Lack of funds
- **Last updated:** 2024-10-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04952571

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04952571, "Combined Treatment of Camrelizumab and Bevacizumab for Adult Patients with Recurrent Glioblastoma (GBM)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04952571. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*